Latest / Durham News Today | 2 Min News | The Daily News Now!
Agenus Focuses on ROBBIN Trial | Durham News
Agenus is pivoting its colon cancer strategy, ditching the BATTMAN study to focus all resources on the high-potential ROBBIN trial—testing BOT+BAL before surgery for high-risk patients. With an $85M upfront investment and potential for over $300M more if warrants are exercised, the company aims to launch patient enrollment in Q1 2027, deliver early data by late 2027, and unveil full results by 2029–2030. Investors are rallying behind this concentrated, earlier-intervention approach, sending the stock soaring—and giving Agenus a clear runway to 2031, though at the cost of shareholder dilution…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.